id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1247-0005,FDA,FDA-2012-E-1247,"Determination of Regulatory Review Period for Purposes of Patent
Extension; BELVIQ",Notice,Determinations,2016-09-23T04:00:00Z,2016,9,2016-09-23T04:00:00Z,2016-11-23T04:59:59Z,2024-02-02T16:36:53Z,2016-22937,0,0,090000648225ae65
FDA-2012-E-1247-0004,FDA,FDA-2012-E-1247,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-18T04:00:00Z,2016,8,2016-08-18T04:00:00Z,,2016-08-18T13:11:04Z,,0,0,09000064821807bf